Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: Two case reports Case Reports

BMC Research Notes

Volumn 9, Issue 1, 2016, Pages

  Chonan, Masashi ^a   Narita, Norio ^b   Tominaga, Teiji ^c  

^a Iwaki Kyoritsu General Hospital   (Japan)

^b Kesennuma City Hospital   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brain metastasis; EGFR mutation; Gefitinib; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; QUINAZOLINE DERIVATIVE;

AGED; BRAIN NEOPLASMS; CASE REPORT; DIAGNOSTIC IMAGING; FATALITY; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MIDDLE AGED; MUTATION; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REMISSION; SECONDARY; THORAX RADIOGRAPHY;

AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FATAL OUTCOME; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MUTATION; QUINAZOLINES; RADIOGRAPHY, THORACIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION;

EID: 84952786923     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-015-1834-0     Document Type: Article

References (9)

1. Noronha V, Joshi A, Gokarn A, Sharma V, Patil V, Janu A, et al. The importance of brain metastasis in EGFR mutation positive NSCLC patients. Chemother Res Pract. 2014;2014:856156.
2. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012;7(9):1417-22.
3. Nagai Y, Miyazawa H, Huqun Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005;65(16):7276-82.
4. Hsiung CY, Leung SW, Wang CJ, Lo SK, Chen HC, Sun LM, et al. The prognostic factors of lung cancer patients with brain metastases treated with radiotherapy. J Neurooncol. 1998;36(1):71-7.
5. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv. 2009;6(10):1017-32.
6. Cappuzzo F, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo M, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer. 2003;41(2):227-31.
7. Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29(3):279-86.
8. Shaw MG, Ball DL. Treatment of brain metastases in lung cancer: strategies to avoid/reduce late complications of whole brain radiation therapy. Curr Treat Options Oncol. 2013;14(4):553-67.
9. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27(9):1394-400.